Cargando…

Effects of Statins on Cardiorenal Syndrome

Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yagi, Shusuke, Aihara, Ken-ichi, Ikeda, Yasumasa, Akaike, Masashi, Sata, Masataka, Matsumoto, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390040/ https://www.ncbi.nlm.nih.gov/pubmed/22792467 http://dx.doi.org/10.1155/2012/162545

Ejemplares similares

Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome
por: Aihara, Ken-ichi, et al.
Publicado: (2010)

n-3 Polyunsaturated Fatty Acids: Promising Nutrients for Preventing Cardiovascular Disease
por: Yagi, Shusuke, et al.
Publicado: (2017)

Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice
por: Mitsuhashi, Takeshi, et al.
Publicado: (2018)

Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7)
por: Yagi, Shusuke, et al.
Publicado: (2015)

Association of Decreased Docosahexaenoic Acid Level After Statin Therapy and Low Eicosapentaenoic Acid Level with In-Stent Restenosis in Patients with Acute Coronary Syndrome
por: Yagi, Shusuke, et al.
Publicado: (2019)

Association of lower limb muscle mass and energy expenditure with visceral fat mass in healthy men
por: Yagi, Shusuke, et al.
Publicado: (2014)

Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Yagi, Shusuke, et al.
Publicado: (2015)

Reduced ratio of eicosapentaenoic acid and docosahexaenoic acid to arachidonic acid is associated with early onset of acute coronary syndrome
por: Yagi, Shusuke, et al.
Publicado: (2015)

Erratum to: ‘Reduced ratio of eicosapentaenoic acid and docosahexaenoic acid to arachidonic acid is associated with early onset of acute coronary syndrome’
por: Yagi, Shusuke, et al.
Publicado: (2015)

Serum concentration of eicosapentaenoic acid is associated with cognitive function in patients with coronary artery disease
por: Yagi, Shusuke, et al.
Publicado: (2014)

Cardiorenal syndrome
por: Schetz, Miet
Publicado: (2009)

Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension
por: Yagi, Shusuke, et al.
Publicado: (2015)

Biomarkers in Cardiorenal Syndrome
por: Goffredo, Giovanni, et al.
Publicado: (2021)

Cardiorenal Syndromes and Sepsis
por: Chelazzi, C., et al.
Publicado: (2011)

Biomarkers in Cardiorenal Syndromes
por: Fu, Shihui, et al.
Publicado: (2018)

Range of adiposity and cardiorenal syndrome
por: Pazos, Fernando
Publicado: (2020)

The Cardiorenal Syndrome: Making the Connection
por: Viswanathan, Gautham, et al.
Publicado: (2010)

The Cardiorenal Syndrome: A Review
por: Shah, B. N., et al.
Publicado: (2010)

Pharmacological Management of Cardiorenal Syndromes
por: House, Andrew A., et al.
Publicado: (2011)

Cardiorenal Syndromes: Pathophysiology to Prevention
por: McCullough, Peter A.
Publicado: (2010)

An Occluded Hooklet of an Embedded Inferior Vena Cava Filter
por: Yagi, Shusuke, et al.
Publicado: (2018)

Long-surviving Anomalous Origin of the Right Pulmonary Artery from the Ascending Aorta Complicated with Pulmonary Arteriovenous Fistula
por: Ueno, Rie, et al.
Publicado: (2019)

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
por: Yagi, Shusuke, et al.
Publicado: (2017)

The Cardiorenal Syndrome
por: Rosner, Mitchell H., et al.
Publicado: (2011)

Cardiorenal syndrome
por: Ye, Wen Qing Wendy, et al.
Publicado: (2023)

An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome
por: Raina, Rupesh, et al.
Publicado: (2020)

Kidney Replacement Therapy in Cardiorenal Syndromes
por: Patschan, Daniel, et al.
Publicado: (2022)

Renal Assessment in Acute Cardiorenal Syndrome
por: Łagosz, Piotr, et al.
Publicado: (2023)

Inhibition of S1P Receptor 2 Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice
por: Ganbaatar, Byambasuren, et al.
Publicado: (2021)

The Role of Imaging in the Management of Cardiorenal Syndrome
por: George, Sajid Melvin, et al.
Publicado: (2011)

Cardiac Resynchronization Therapy in the Cardiorenal Syndrome
por: Davis, Margot K., et al.
Publicado: (2011)

Correction of Iron Deficiency in the Cardiorenal Syndrome
por: Silverberg, Donald S., et al.
Publicado: (2011)

Cardiorenal Syndrome: An Unsolved Clinical Problem
por: Martínez-Santos, Paula, et al.
Publicado: (2011)

Therapeutic Options for the Management of the Cardiorenal Syndrome
por: Koniari, Katerina, et al.
Publicado: (2010)

Cardiorenal Syndrome: New Pathways and Novel Biomarkers
por: Gembillo, Guido, et al.
Publicado: (2021)

Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice
por: Suto, Kumiko, et al.
Publicado: (2021)

Heart-Kidney Interaction: Epidemiology of Cardiorenal Syndromes
por: Cruz, Dinna N., et al.
Publicado: (2010)

ADPKD: Prototype of Cardiorenal Syndrome Type 4
por: Virzì, Grazia Maria, et al.
Publicado: (2010)

Advances in the Pathogenesis of Cardiorenal Syndrome Type 3
por: Clementi, Anna, et al.
Publicado: (2015)

Cardiorenal syndrome in thalassemia patients
por: Makmettakul, Sorasak, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q121n02f48690lbc6m00a3kp2d